Browse > Article
http://dx.doi.org/10.4014/jmb.1704.04035

Alteration of DNA Methylation in Gastric Cancer with Chemotherapy  

Choi, Su Jin (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University)
Jung, Seok Won (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University)
Huh, Sora (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University)
Chung, Yoon-Seok (Division of Viral Diseases Center for Laboratory Control of Infectious Disease, Korea Centers for Disease Control and Prevention)
Cho, Hyosun (College of Pharmacy and Innovative Drug Center, Duksung Women's University)
Kang, Hyojeung (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University)
Publication Information
Journal of Microbiology and Biotechnology / v.27, no.8, 2017 , pp. 1367-1378 More about this Journal
Abstract
Epigenetic alterations such as DNA methylation, histone acetylation, and chromatin remodeling can control gene expression by regulating gene transcription. DNA methylation is one of the frequent epigenetic events that play important roles in cancer development. Cancer cells can gain significant resistance to anticancer drugs and escape programmed cell death through major epigenetic changes, including DNA methylation. To date, several research groups have identified instances of both (i) hypermethylation of tumor suppressor genes, and (ii) global hypomethylation of oncogenes. These changes in DNA methylation status could be used as biomarkers for the diagnosis and prognosis of cancer patients undergoing chemotherapies or other clinical therapies. Herein, we describe genes for which methylation is dependent upon anticancer drug resistance in patients with gastric cancer; we then suggest a significant epigenetic target to focus on for overcoming anticancer drug resistance.
Keywords
DNA methylation; gastric cancer; chemoresistance; cisplatin; 5-FU;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Shen J, Wei J, Wang H, Yang Y, Yue G, Wang L, et al. 2013. SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen. PLoS One 8: e75564.   DOI
2 Zhou W, Wang J, Man WY, Zhang QW, Xu WG. 2015. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Asian Pac. J. Cancer Prev. 16: 2425-2430.   DOI
3 Subhash VV, Tan SH, Tan WL, Yeo MS, Xie C, Wong FY, et al. 2015. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer 15: 550.   DOI
4 Yeh CM, Chang LY, Lin SH, Chou JL, Hsieh HY, Zeng LH, et al. 2016. Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer. Sci. Rep. 6: 31690.   DOI
5 Jeon MS, Song SH, Yun J, Kang JY, Kim HP, Han SW, et al. 2016. Aberrant epigenetic modifications of LPHN2 function as a potential cisplatin-specific biomarker for human gastrointestinal cancer. Cancer Res. Treat. 48: 676-686.   DOI
6 Su C, Li J, Cao Y, Xiao L, Shi C. 2017. Long noncoding RNA HOTAIR promotes cisplatin resistance in gastric cancer through promoting WIF-1 promoter methylation. Int. J. Clin. Exp. Med. 10: 2717-2726.
7 Sugita H, Iida S, Inokuchi M, Kato K, Ishiguro M, Ishikawa T, et al. 2011. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol. Rep. 25: 513.
8 Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H, Watanabe M. 2013. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. Mol. Cancer Res. 11: 1362-1374.   DOI
9 Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, et al. 2008. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int. J. Cancer 122: 603-608.   DOI
10 Kwon OH, Park JL, Baek SJ, Noh SM, Song KS, Kim SY, et al. 2013. Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5-fluorouracil of gastric cancer cells. Cancer Sci. 104: 391-397.   DOI
11 Hu X, Sui X, Li L, Huang X, Rong R, Su X, et al. 2013. Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J. Pathol. 229: 62-73.   DOI
12 Maeda O, Ando T, Ohmiya N, Ishiguro K, Watanabe O, Miyahara R, et al. 2014. Alteration of gene expression and DNA methylation in drug-resistant gastric cancer. Oncol. Rep. 31: 1883-1890.   DOI
13 Xia LL, Tang YB, Song FF, Xu L, Ji P, Wang SJ, et al. 2016. DCTPP1 attenuates the sensitivity of human gastric cancer cells to 5-fluorouracil by up-regulating MDR1 expression epigenetically. Oncotarget 7: 68623-68637.   DOI
14 Zhang Y, Ye WY, Wang JQ, Wang SJ, Ji P, Zhou GY, et al. 2013. dCTP Pyrophosphohydrase exhibits nucleic accumulation in multiple carcinomas. Eur. J. Histochem. 57: e29.   DOI
15 Sun J, Du N, Li J, Zhou J, Tao G, Sun S, et al. 2016. Transcription factor AP2$\varepsilon$. Technol. Cancer Res. Treat. 15: 285-295.   DOI
16 Zhang Y, Qu X, Jing W, Hu X, Yang X, Hou K, et al. 2009. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Anti cancer Drugs 20: 208-214.   DOI
17 Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y, et al. 2014. Methylation of miR-129-5p CpG island modulates multidrug resistance in gastric cancer by targeting ABC transporters. Oncotarget 5: 11552-11563.   DOI
18 Yu Y, Yan W, Liu X, Jia Y, Cao B, Yu Y, et al. 2014. DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. Am. J. Cancer Res. 4: 710.
19 Gou WF, Yang XF, Shen DF, Zhao S, Liu YP, Sun HZ, et al. 2015. The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy. Oncotarget 6: 19841-19867.   DOI
20 Mi H, Muruganujan A, Thomas PD. 2013. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 41: D377-D386.
21 Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14: 128.   DOI
22 Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53: 615-627.   DOI
23 Baylin SB. 2005. DNA methylation and gene silencing in cancer. Nat. Rev. Clin. Oncol. 2: S4.   DOI
24 Das PM, Singal R. 2004. DNA methylation and cancer. J. Clin. Oncol. 22: 4632-4642.   DOI
25 Fu D-G. 2015. Epigenetic alterations in gastric cancer (Review). Mol. Med. Rep. 12: 3223-3230.   DOI
26 Kang C, Song J-J, Lee J, Kim MY. 2014. Epigenetics: an emerging player in gastric cancer. World J. Gastroenterol. 20: 6433-6447.   DOI
27 Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. 2004. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol. 164: 689-699.   DOI
28 Li L, Li C, Mao H, Du Z, Chan WY, Murray P, et al. 2016. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci. Rep. 6: 26591.   DOI
29 Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. 2013. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13: 714-726.   DOI
30 Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. 2014. Drug resistance in cancer: an overview. Cancers 6: 1769-1792.   DOI
31 Chen C-C, Lee K-D, Pai M-Y, Chu P-Y, Hsu C-C, Chiu C-C, et al. 2015. Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells. Cancer Cell Int. 15: 98.   DOI
32 Carcas LP. 2014. Gastric cancer review. J. Carcinog. 13: 14.   DOI
33 Guo X, Xia J, Yan J. 2015. Promoter methylated microRNAs: potential therapeutic targets in gastric cancer (Review). Mol. Med. Rep. 11: 759-765.   DOI
34 Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, et al. 2013. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 62: 22-33.   DOI
35 Kang KA, Piao MJ, Kim KC, Kang HK, Chang WY, Park IC, et al. 2014. Epigenetic modification of Nrf2 in 5-fluorouracilresistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis. 5: e1183.   DOI
36 Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, et al. 2007. Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J. Gastroenterol. 42: 866-873.   DOI
37 Florea A-M, Busselberg D. 2011. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3: 1351-1371.   DOI
38 Stewart DJ. 2007. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63: 12-31.   DOI
39 Napieralski R, Ott K, Kremer M, Becker K, Boulesteix A-L, Lordick F, et al. 2007. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin. Cancer Res. 13: 5095-5102.   DOI